Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662541 | 1.00 | MAPT (0.50) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL28758700 | 0.84 | ALDH1A1 (0.55) | MAPTALDH1A1TDP1SMN1; SMN2HTT | |
| SCHEMBL29186391 | 0.81 | MAPT (0.47) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL29788822 | 0.81 | NOS3 (0.43) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL2473152 | 0.81 | NOS3 (0.43) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL2551316 | 0.81 | TDP1 (0.51) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL535781 | 0.80 | MAPT (0.44) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL1981976 | 0.80 | DYRK1A (0.41) | MAPTLMNAALDH1A1TDP1HTT | |
| SCHEMBL31086675 | 0.80 | DYRK1A (0.41) | MAPTLMNAALDH1A1TDP1HTT | |
| SCHEMBL2554438 | 0.80 | DYRK1A (0.42) | MAPTLMNAALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717162-A | Urea derivatives as kinase inhibitors | 奥苏拉收购有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-9890185-B2 | Urea derivatives useful as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-2370429-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010112936-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112936-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | MAPT 2621/4885LMNA 1997/4885ALDH1A1 755/4885 |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | MAPT 4618/4885LMNA 2027/4885ALDH1A1 3995/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | MAPT 1600/4885LMNA 2580/4885ALDH1A1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.